Argatroban: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name = (2''R'',4''R'')-1-[(2''S'')-5-(diaminomethylideneamino)-2-<br><nowiki>[</nowiki>[(3''R'')-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]<br>sulfonylamino]pentanoyl]-4-methyl-piperidine-2-<br>carboxylic acid
{{Argatroban}}
| image = Argatroban_svg.png
{{CMG}}; {{AE}} {{JH}}
| CAS_number = 74863-84-6
| ATC_prefix = B01
| ATC_suffix = AE03
| ATC_supplemental =
| PubChem = 152951
| DrugBank = APRD00105
| C=23 | H=36 | N=6 | O=5 | S=1
| molecular_weight = 508.635 g/mol
| bioavailability =  100% (intravenous)
| protein_bound = 54%
| metabolism = hepatic
| elimination_half-life = 39 and 51 minutes
| pregnancy_category =
| legal_status =
| routes_of_administration = intravenous
}}
{{SI}}
{{CMG}}{{JH}}


==Overview==


'''Argatroban''' is an [[anticoagulant]] that is a small molecule [[direct thrombin inhibitor]].  In 2000, argatroban was licensed by the [[Food and Drug Administration]] (FDA) for prophylaxis or treatment of [[thrombosis]] in patients with [[heparin-induced thrombocytopenia|heparin-induced thrombocytopenia (HIT)]].  In 2002, it was approved for use during [[Angioplasty|percutaneous coronary interventions]] in patients who have or at risk for developing [[HIT]].


'''Argatroban''' is an [[anticoagulant]] that is a small molecule [[direct thrombin inhibitor]].  In 2000, argatroban was licensed by the [[Food and Drug Administration]] (FDA) for prophylaxis or treatment of [[thrombosis]] in patients with [[heparin-induced thrombocytopenia]].  In 2002, it was approved for use during [[Angioplasty|percutaneous coronary interventions]] in patients who have or at risk for developing HIT.
Argatroban is given intravenously.  Argatroban is metabolized in the [[liver]] and has a half life of about 50 minutes.  It is monitored by [[PTT]].  Because of its hepatic metabolism, it may be used in patients with [[renal dysfunction]].  (This is in contrast to [[lepirudin]], a [[direct thrombin inhibitor]] that is primarily renally cleared).
 
Argatroban is given intravenously.  Argatroban is metabolized in the [[liver]] and has a half life of about 50 minutes.  It is monitored by PTT.  Because of its hepatic metabolism, it may be used in patients with renal dysfunction.  (This is in contrast to [[lepirudin]], a direct thrombin inhibitor that is primarily renally cleared).


It is manufactured by [[GlaxoSmithKline]].
It is manufactured by [[GlaxoSmithKline]].
Line 31: Line 13:
==Category==
==Category==


ADP receptor inhibitors;Triazolopyrimidines;Organofluorides;Alcohols;AstraZeneca
Anticoagulants; Direct Thrombin Inhibitor


==FDA Package Insert==
==FDA Package Insert==


====BRILINTA (ticagrelor) tablet ====
====ARGATROBAN injection, solution====


'''  [[Ticagrelor indications and usage|Indications and Usage]]'''
'''  [[Argatroban indications and usage|Indications and Usage]]'''
'''| [[Ticagrelor dosage and administration|Dosage and Administration]]'''
'''| [[Argatroban dosage and administration|Dosage and Administration]]'''
'''| [[Ticagrelor dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Argatroban dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[Ticagrelor contraindications|Contraindications]]'''
'''| [[Argatroban contraindications|Contraindications]]'''
'''| [[Ticagrelor warnings and precautions|Warnings and Precautions]]'''
'''| [[Argatroban warnings and precautions|Warnings and Precautions]]'''
'''| [[Ticagrelor adverse reactions|Adverse Reactions]]'''
'''| [[Argatroban adverse reactions|Adverse Reactions]]'''
'''| [[Ticagrelor drug interactions|Drug Interactions]]'''
'''| [[Argatroban drug interactions|Drug Interactions]]'''
'''| [[Ticagrelor use in specific populations|Use in Specific Populations]]'''
'''| [[Argatroban use in specific populations|Use in Specific Populations]]'''
'''| [[Ticagrelor overdosage|Overdosage]]'''
'''| [[Argatroban overdosage|Overdosage]]'''
'''| [[Ticagrelor description|Description]]'''
'''| [[Argatroban description|Description]]'''
'''| [[Ticagrelor clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Argatroban clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Ticagrelor nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Argatroban nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[Ticagrelor clinical studies|Clinical Studies]]'''
'''| [[Argatroban clinical studies|Clinical Studies]]'''
'''| [[Ticagrelor how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Argatroban how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Ticagrelor patient counseling information|Patient Counseling Information]]'''
'''| [[Argatroban patient counseling information|Patient Counseling Information]]'''
'''| [[Ticagrelor labels and packages|Labels and Packages]]'''
'''| [[Argatroban labels and packages|Labels and Packages]]'''


==Reference==


==Reference==
* Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. ''[[N Engl J Med]]'' 2005;353:1028-40. PMID 16148288.
* Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. ''[[N Engl J Med]]'' 2005;353:1028-40. PMID 16148288.


==External links==
==External links==
*[http://www.argatroban.com GlaxoSmithKline's website on argatroban]
*[http://www.argatroban.com GlaxoSmithKline's website on argatroban]


{{Antithrombotics}}
{{Antithrombotics}}


 
[[Category:Cardiology]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Anticoagulants]]
[[Category:Anticoagulants]]
[[Category:Drugs]]
[[Category:Drugs]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[de:Argatroban]]

Revision as of 23:04, 3 March 2014

Argatroban
Argatroban® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Overview

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have or at risk for developing HIT.

Argatroban is given intravenously. Argatroban is metabolized in the liver and has a half life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

It is manufactured by GlaxoSmithKline.

Category

Anticoagulants; Direct Thrombin Inhibitor

FDA Package Insert

ARGATROBAN injection, solution

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Reference

  • Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. PMID 16148288.

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Argatroban&oldid=949996"